Alison Conlin

6.5k citations

73 papers · 1.8k indexed · 2 hit papers · h-index 23

Impact in

Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Colorectal Cancer Treatments and Studies
Genetics top 5%
- Glioma Diagnosis and Treatment

Papers in

Oncology 59
- Cancer Treatment and Pharmacology 28
- HER2/EGFR in Cancer Research 22
- Cancer survivorship and care 13
- Cancer Immunotherapy and Biomarkers 7
Pulmonary and Respiratory Medicine 33
- Advanced Breast Cancer Therapies 18
- Brain Metastases and Treatment 8
- Cancer-related cognitive impairment studies 6

Co-authors: Andrew D. Seidman Supriya G. Mohile Erika Hamilton Michelle C. Janelsins Karen M. Mustian Virginia F. Borges Jorge Chaves Todd Gray
Journals: Journal of Clinical Oncology (25 papers)Cancer Research (6 papers)Clinical Breast Cancer (4 papers)Annals of Oncology (4 papers)Gut (3 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Alison Conlin

70 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update 2025 · 18 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Journal of Clinical Oncology
2017 Journal of Clinical Oncology

Peers

Countries citing papers authored by Alison Conlin

Since Specialization

Citations

This map shows the geographic impact of Alison Conlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Conlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Conlin more than expected).

Fields of papers citing papers by Alison Conlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Conlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Conlin. The network helps show where Alison Conlin may publish in the future.

Co-authors

The 25 scholars most cited alongside Alison Conlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alison Conlin Line = papers co-authored together Alison Conlin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update Journal of Clinical Oncology ·Ko Un Park, Mark R. Somerfield, Nirupama Anne, Muriel Brackstone, Alison Conlin, Henrique Lima Couto, Lynn T. Dengel, Andrea Eisen, Brittany Harvey, Jeffrey Hawley, Janice N. Kim, Nwamaka Lasebikan, Elizabeth S. McDonald, Deepti Pradhan, Samantha Shams, Raymond B. Mailhot Vega, Alastair M. Thompson, Mylin A. Torres Hit paper breakdown →	2025	18
2	Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study Frontiers in Oncology ·Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L. Puhalla, Alison Conlin, E. Claire Dees, Muralidhar Beeram, Sonya C. Chapman, Andrew Lithio, Lacey M. Litchfield, Matthew P. Goetz	2025	0
3	Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia PubMed ·Brian J. Altman, Po‐Ju Lin, Lindsey Jean Mattick, Elliot Outland, Javier Bautista, Chin‐Shang Li, Umang Gada, Kristina M. Morris, Amelia Clark, Daniel Mwangi, Rachel E. DeRollo, Amber S. Kleckner, Ian R. Kleckner, Nikesha Gilmore, Benjamin Esparaz, Amarinthia Curtis, Alison Conlin, Gianni Monaco, Jacob Hughey, Karen M. Mustian	2025	1
4	Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results Breast Cancer Research ·Erika Hamilton, Manish Patel, Virginia F. Borges, Jane Meisel, Meena Okera, Carlos Alemany, Timothy Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, Nancy U. Lin	2025	2
5	Walking dose required to achieve a clinically meaningful reduction in cancer-related fatigue among patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide prospective cohort study. Journal of Clinical Oncology ·Lindsey Jean Mattick, Po‐Ju Lin, Karen M. Mustian, Luke J. Peppone, Umang Gada, Stephen Rajan Samuel, Viktor Clark, Sule Yilmaz, Jeremy McGuire, Alison Conlin, Lora Weiselberg, Jerry W. Mitchell, Michelle C. Janelsins	2024	0
6	382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer Annals of Oncology ·Nancy U. Lin, Virginia F. Borges, Manish R. Patel, Meena Okera, Jane Meisel, Robert Wesolowski, Timothy Pluard, Kathy D. Miller, Nicole McCarthy, Alison Conlin, Reshma Mahtani, Dhanusha Sabanathan, Kelly McCann, Erin Roesch, G. Mathauda-Sahota, Joerg H. Schroeder, Erika Hamilton	2023	7
7	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222 Clinical Cancer Research ·Halle C. F. Moore, William E. Barlow, George Somlo, Julie R. Gralow, Anne F. Schott, Daniel F. Hayes, Peter Kühn, James Hicks, Lisa Welter, Philip A. Dy, Christina Yeon, Alison Conlin, Ernie Balcueva, Danika L. Lew, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobágyi	2021	8
8	Relationships of self-perceived age with geriatric assessment domains in older adults with cancer Journal of Geriatric Oncology ·Kah Poh Loh, Paul R. Duberstein, Jason Zittel, Lianlian Lei, Eva Culakova, Huiwen Xu, Sandy Plumb, Marie Flannery, Allison Magnuson, Javier Bautista, Marsha Wittink, Nikesha Gilmore, Valerie Targia, Alison Conlin, Jeffrey L. Berenberg, Victor G. Vogel, Supriya G. Mohile	2019	8
9	Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study The Lancet Oncology ·Rashmi K. Murthy, Virginia F. Borges, Alison Conlin, Jorge Chaves, Marc C. Chamberlain, Todd Gray, Alex Vo, Erika Hamilton	2018	129
10	Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies Annals of Oncology ·Stacy L. Moulder, Erika Hamilton, Cristiano Ferrario, Alison Conlin, Ian E. Krop, M. Chamberlain, Todd Gray, Virginia F. Borges	2017	2
11	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 Clinical Breast Cancer ·John W. Smith, Marc Buyse, Priya Rastogi, Charles E. Geyer, Samuel A. Jacobs, Érica Patocskai, André Robidoux, Alison Conlin, Bilal Ansari, George P. Keogh, Philip J. Stella, Howard M. Gross, Raymond S. Lord, Jonathan Polikoff, Celine Mauquoi, Eleftherios P. Mamounas, Sandra M. Swain, Norman Wolmark	2016	8
12	Phase II trial of patupilone in patients with brain metastases from breast cancer Neuro-Oncology ·D. Peereboom, Conleth G. Murphy, Manmeet S. Ahluwalia, Alison Conlin, April F. Eichler, Catherine Van Poznak, Joseph Baar, Paul Elson, Andrew D. Seidman	2014	22
13	Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer Clinical Breast Cancer ·Andrew D. Seidman, Alison Conlin, Ariadne M. Bach, Mary Ellen Moynahan, Diana Lake, Andres Forero, Gail S. Wright, Mary Helen Hackney, Alicia Clawson, Larry Norton, Clifford A. Hudis	2013	29
14	Multi-centre audit to determine factors associated with success and failure in treating colonic obstruction with self expanding metals stents (SEMS) Gut ·Joe Geraghty, M. J. Mcmahon, Alison Conlin, S Alam, T Gledhill, (unknown), Jesse Hill, S. Lee, Gordon Carlson, Derrick Martin, Paul W. O’Toole, Jayapal Ramesh, S Lal, Robert P. Willert, Keith Bodger, S Sarkar, (unknown)	2011	2
15	Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays Annals of Oncology ·Edi Brogi, Conleth G. Murphy, Matthew Johnson, Alison Conlin, Melinda Laine Hsu, Sujata Patil, M. Akram, Tatjana Nehhozina, Komal Jhaveri, C. Hudis, A. D. Seidman	2011	30
16	Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer Clinical Breast Cancer ·Alison Conlin, Andrew D. Seidman, Ariadne M. Bach, Diana Lake, Maura N. Dickler, Gabriella D’Andrea, Tiffany A. Traina, Michael Danso, Adam Brufsky, Mansoor N. Saleh, Alicia Clawson, Clifford A. Hudis	2010	70
17	Dusp1/mkp-1, dusp2/hpac1 and dusp8/vh5 expression in colorectal cancer Gut ·Alison Conlin, R. Steele, C. Roland Wolf	2008	1
18	Beyond Cytotoxic Chemotherapy for the First-Line Treatment of HER2-Negative, Hormone-Insensitive Metastatic Breast Cancer: Current Status and Future Opportunities Clinical Breast Cancer ·Alison Conlin, Andrew D. Seidman	2008	27
19	Taxanes in breast cancer: An update Current Oncology Reports ·Alison Conlin, Andrew D. Seidman	2007	38
20	Use of the Oncotype DX™ 21-Gene Assay to Guide Adjuvant Decision Making in Early-Stage Breast Cancer Molecular Diagnosis & Therapy ·Alison Conlin, Andrew D. Seidman	2007	14

About Alison Conlin

Alison Conlin is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Geriatrics and Gerontology, Cancer Research and Dermatology, having authored 73 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (28 papers), HER2/EGFR in Cancer Research (22 papers), Advanced Breast Cancer Therapies (18 papers), Cancer survivorship and care (13 papers), Brain Metastases and Treatment (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Breast Cancer Treatment Studies (7 papers) and Cancer-related cognitive impairment studies (6 papers). The work is most often cited by research in Oncology (1.1k citations), Genetics (226 citations), Pulmonary and Respiratory Medicine (663 citations), Geriatrics and Gerontology (62 citations) and Cancer Research (222 citations). Alison Conlin has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Andrew D. Seidman, Supriya G. Mohile, Erika Hamilton, Michelle C. Janelsins, Karen M. Mustian, Virginia F. Borges, Jorge Chaves, Todd Gray, Charles E. Heckler and Alex Vo. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Breast Cancer, Annals of Oncology and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact